Tons of shares were moved last weeks, mostly at prices far above actual pps. Not only wild speculation justifies those volumes and not all buyers "evacuated" their positions even with the following massive short attack, similar but not great in magnitude. Based on expected demand for antiviral treatment to stop ebola outbreaks, mainly in west african countries, to avoid other continents' large scale infection, IBIO may have the opportunity to sell its technology and capitalize the important investment in R&D made over the last decade to develop efficient methods to rapidly produce pharmaceutics from plants.